News With all eyes on IO, Tagrisso could be AZ's ace card AstraZeneca saw revenues decline by 3% and earnings per share fall 5% in 2016 as the expiry of blockbuster Crestor took its toll.
News Can Keytruda beat Opdivo to full UK access in lung cancer? A decisive moment in lung cancer treatment is nearing
News BMS and Nektar to pair Opdivo with natural killer cell drug BMS and Nektar's combination latest in frenzied immunotherapy field
News Merck makes its move: Keytruda filed for first line lung can... Merck steals a march on rival BMS.
News BMS' Opdivo stumbles in lung cancer, but could still maintai... Analysts expect Opdivo to recover via combination trials
News GSK sets up Nucala and Dupixent showdown in COPD GSK has said new data leads it to believe Nucala will be "highly competitive" with rival biologic Dupixent in COPD - if it gets approved by the FDA.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
